“…The therapeutic benefit of pallidal DBS has been widely established in the dystonic syndrome irrespective of primary, 1,[5][6][7]10,12,14,16,19,20,22,29 secondary, or heredodegenerative dystonia. 15,39,41 Some studies found the DYT1 mutation to be a prognostic factor of a successful outcome of pallidal DBS, [3][4][5]13,37,42 while others did not.…”